Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.
Cho I, Hong S, et al. • Journal of clinical hypertension (Greenwich, Conn.) • 2026
Triple combination therapy with valsartan/amlodipine/chlorthalidone demonstrated superior blood pressure reduction and a favorable safety profile in patients with essential hypertension inadequately controlled on valsartan/amlodipine dual therapy, supporting its use as an effective treatment option in this population.
Key Findings
Results
The single-pill triple combination of Val/Aml/CTD produced significantly greater reduction in mean sitting systolic blood pressure compared to dual therapy with Val/Aml.
The least squares mean ± SE change in MSSBP was -19.70 ± 1.31 mmHg in the Val/Aml/CTD group versus -8.71 ± 1.26 mmHg in the control group.
The between-group difference was -10.99 ± 1.81 mmHg (95% CI, -14.56 to -7.41; p < 0.0001).
The primary endpoint was change in MSSBP from baseline to week 8.
Patients were randomized 1:1 using a double-dummy design.
Results
No serious adverse events occurred in the triple combination therapy group, compared to a 1.98% incidence in the dual therapy control group.
The difference in serious adverse event incidence between groups was not statistically significant (p = 0.4985).
The triple combination therapy was described as having 'a favorable safety profile.'
193 patients were randomized, and 178 completed the study.
Methods
The study employed a dose-escalation design over a 6-week active treatment period following a 4-week run-in phase on dual therapy.
Patients whose blood pressure remained uncontrolled after 4 weeks of Val/Aml 80/5 mg were randomized.
Initial randomized doses were Val/Aml/CTD 80/5/12.5 mg or Val/Aml 80/5 mg.
After 2 weeks, doses were escalated to Val/Aml/CTD 160/5/25 mg or Val/Aml 160/5 mg for the remaining 4 weeks.
Total treatment duration after randomization was 6 weeks, with the primary endpoint assessed at week 8 (inclusive of the run-in period).
Background
Many hypertensive patients require three or more antihypertensive agents to achieve target blood pressure, motivating the development of single-pill triple combination therapies.
The study was conducted in South Korea as a randomized, double-blind, multicenter phase 3 trial.
The trial was prospectively registered at ClinicalTrials.gov (identifier: NCT06416865).
The patient population consisted of those with essential hypertension inadequately controlled on dual therapy.
What This Means
This research suggests that combining three blood pressure medications—valsartan, amlodipine, and chlorthalidone—into a single pill is significantly more effective at lowering systolic blood pressure than continuing with just two of those medications (valsartan and amlodipine). In a clinical trial conducted in South Korea, patients whose blood pressure was not adequately controlled on the two-drug combination were switched either to the three-drug pill or kept on the two-drug regimen. After about eight weeks total, those taking the three-drug pill saw their systolic blood pressure drop by nearly 20 mmHg on average, compared to roughly 9 mmHg in the two-drug group—a clinically meaningful difference of about 11 mmHg.
The safety results were also reassuring: no serious adverse events occurred among patients taking the triple combination pill, while a small number (about 2%) of those in the two-drug control group did experience serious adverse events. This suggests the added medication did not introduce meaningful new safety risks in this study population.
This research matters because high blood pressure often requires more than one or two medications to reach safe levels, and managing multiple pills can be difficult for patients. A single pill containing three medications could simplify treatment, potentially improving adherence. This study provides evidence supporting the use of this specific triple combination as a treatment option for people whose blood pressure remains uncontrolled on two-drug therapy.
Cho I, Hong S, Kong M, Jo S, Cho E, Choi C, et al.. (2026). Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.. Journal of clinical hypertension (Greenwich, Conn.). https://doi.org/10.1111/jch.70362